Aggrastat Injection, Solution
Product Images NDC 25208-902

Aggrastat Injection is a prescription drug used for intravenous use to prevent blood clots. It comes in a 15mL single-dose vial of 3.75 mg per injection, and any unused portion should be discarded. The drug should be protected from light during storage. Aggrastat Injection is distributed by Medicure Pharma in Princeton, NJ. More information can be found in the accompanying insert or carton. The usual adult dosage is not available.*

AGGRASTAT® (tirofiban hydrochloride) Injection is a pre-mixed injection for bolus with a usual adult dosage of 0.25 g of tirofiban. The injection should be used for intravenous use only and must be protected from light during storage at a temperature range of 15-30°C. The pH of the injection may be adjusted using hydrochloric acid and/or sodium hydroxide. Distributed by Medicure Pharma, Inc.*

The text is a table showing the proportion with endpoint and risk reduction for two different treatment options (Heparin and AGGRASTAT + Heparin) for a composite endpoint at 180-day follow-up. The table also includes study day values.*

Not available.*

This is a medical calculation for determining the dosage volume of a medication that is 250 mcg/mL concentration. The dosage is specified as 25 meg/kg multiplied by the body weight in kilograms. The result of this calculation is the bolus volume in milliliters that should be administered.*

This text provides information on how to calculate the bolus volume for a medication. The formula given is 25 meg/kg x body weight (kg), and the resulting bolus volume is given as 50 mcg/mL. This information would be useful for healthcare professionals who need to administer medications to patients.*

This text provides a formula for calculating the infusion rate for a medication based on the patient's body weight and creatinine clearance (CrCl). It suggests using an infusion rate of 0.15 meg/kg/min multiplied by body weight in kilograms and 60 minutes per hour. For patients with a CrCl greater than 60 mL/min, it recommends an infusion rate of 50 mcg/mL.*

This text describes a calculation for finding the infusion rate for administering a medication based on the patient's weight and creatinine clearance. The calculation involves multiplying the weight of the patient, the infusion rate in mcg/kg/min, and the number of minutes per hour. The text then provides a conversion factor for converting the infusion rate from mcg/mL to mL/h. The final result is a specific infusion rate in mL/h for patients whose creatinine clearance is greater than 60 mL/min.*

This is a medical formula to calculate infusion rate based on body weight and creatinine clearance of a patient. The first part of the formula uses weight, and the second part uses creatinine clearance to calculate the infusion rate. The final result is in milliliters per hour.*

AAGGRASTAT® is a medication provided in 250mL single-dose containers to be used intravenously as directed by a physician. Each container houses 125mg/ml of Trofiban hydrochloride corresponding to 12mg of tirofiban, 2.25g of sodium chloride, 135mg of sodium citrate dihydrate, B mg of anhydrous citric acid, and water or injection. It should be administered using a calibrated infusion device and is recommended to be used with premixed 150-smotic sterile nonpyrogenic solution (50 mg per ml). The solution's pH might have been adjusted using sodium hydroxide or hydrochloric acid. Extra precautionary measures regarding storage and usage are also mentioned. This medication is a registered trademark of Medicure International, Inc.*

This is a description for a medication with the NDC number 25208-902-01. The medication is called Rionly. It comes in a single-use 100mL vial with 5mg per 100mL or 50mg per mL concentration of Trofiban hydrochloride, which is a platelet aggregation inhibitor. The medication is iso-osmotic, sterile, and nonpyrogenic. Each vial contains sodium chloride, sodium citrate dihydrate, citric acid anhydrous, and water for injection. The pH may be adjusted with hydrochloric acid and/or sodium hydroxide. It is recommended to be used with a calibrated infusion device, and one should not add supplementary medication. It is also important to check for minute leaks before using the bag as their integrity might be impaired. This medication is intravenously administered as directed by a physician. The recommended storage is at 25°C (77°F) with excursions permitted between 15-30°C (59-86°F). It should be protected from light, and one should not freeze the medication. It is manufactured in Spain by Laboratorios Grifols S.A. for Medicure International, Inc. and distributed by Medicure Pharma, Inc. in Princeton, NJ.*

This text is the description of the medication AGGRASTAT®. AGGRASTAT® is a type of injection used for medicinal purposes containing tirofiban hydrochloride. Each 250mL of AGGRASTAT® contains 12.5mg of tirofiban hydrochloride, Trofnycociarie eutalnt (0125 mg trofn, 225 gsogm chorde, #135mg s crtedyiate, g i i aoytrous, Wte o njecton pHay e been djsted with irochoricacidanor o e. It is sterile, non-pyrogenic, and is-osmatic. AGGRASTAT® should be protected from light during storage and is recommended for use with calibrated infusion devices. The usual dosage is intravenously directed by a physician. There are cautions when using this medication, such as not adding supplementary medication, discarding any cracked or impairedbottles, and not misusing it. AGGRASTAT® should be stored at 5°C with excursions permitted between 15-39°C (59.86°F) and protected from light during storage. It is manufactured by LaboratoriosGrifols S A. and marketed by Medicare International, Inc. AGGRASTAT® is a registered trademark of Vi and AGHONP 2001.*

This is a description of AGGRASTAT® (TIROFIBAN HYDROCHLORIDE) INJECTION contained in a 100mL single-dose container. The medication is available only on prescription and is recommended to be used with a calibrated infusion device. Each 100 mL contains Tirofiban hydrochloride equivalent to 5 mg tirofiban, 900 mg sodium chloride, 54 mg sodium citrate dihydrate, 3.2 mg citric acid anhydrous, Water for Injection. Usual Dosage is intravenously as directed by a physician. The storage temperature is recommended to be between 15-30°C (59-86°F) and the medication should not be frozen and should be protected from light during storage. No additional medication should be added and the solution should not be used unless it is clear.*